Strata Critical Medical, Inc.
SRTA Nasdaq Services-Health Services Financials FY2021–FY2025
Revenue
Total sales reported in the income statement.
$197M
34.3%
vs prior year
Operating margin
Operating income as a share of revenue.
−11.3%
4.0 pts
Net income
Profit after all expenses, interest and tax.
$41.3M
Free cash flow
Cash from operations minus capital spending.
−$58.5M
Return on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
—
Market cap
Last close times the latest diluted share count, so it is approximate.
—
P/E
Last close divided by diluted earnings per share over the last four quarters.
—
On $0.50 EPS (TTM)
What Strata Critical Medical, Inc. does
No business description yet.
- Legal name
- Strata Critical Medical, Inc.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 3, 2026
- Accession · CIK
- 0001628280-26-013628
0001779128
Revenue and margins
Strata Critical Medical, Inc. had $197M of revenue in fiscal 2025, up 34.3% on the year before.
FY21
Revenue $50.5M
FY22
Revenue —
FY23
Revenue $225M
FY24
Revenue $147M
FY25
Revenue $197M
Q3 '23
Revenue $71.4M
Q4 '23
Revenue $47.5M
Q1 '24
Revenue $51.5M
Q2 '24
Revenue $67.9M
Q3 '24
Revenue $36.1M
Q4 '24
Revenue $36.4M
Q1 '25
Revenue $35.9M
Q2 '25
Revenue $45.1M
Q3 '25
Revenue $49.3M
Q4 '25
Revenue $66.8M
Q1 '26
Revenue $67.4M
Q2 '26
Revenue $72.5M
FY21
Gross 20.8%
Operating −47.7%
Net −79.3%
FCF −31.5%
FY22
Gross —
Operating —
Net —
FCF —
FY23
Gross 18.7%
Operating −30.3%
Net −24.9%
FCF −15.3%
FY24
Gross 20.2%
Operating −15.3%
Net −18.6%
FCF −22.7%
FY25
Gross 20.9%
Operating −11.3%
Net 21.0%
FCF −29.7%
Gross
Operating
Net
FCF
Q3 '23
Gross 21.8%
Operating −10.4%
Net 0.4%
FCF 1.9%
Q4 '23
Gross 19.0%
Operating −75.1%
Net −71.5%
FCF −19.7%
Q1 '24
Gross 19.7%
Operating −19.2%
Net −8.2%
FCF −31.8%
Q2 '24
Gross 24.1%
Operating −17.9%
Net −16.7%
FCF −11.4%
Q3 '24
Gross 20.8%
Operating −19.7%
Net −5.4%
FCF −8.2%
Q4 '24
Gross 13.8%
Operating −16.2%
Net −26.9%
FCF −17.4%
Q1 '25
Gross 19.6%
Operating −15.8%
Net −9.7%
FCF −8.0%
Q2 '25
Gross 20.0%
Operating −10.3%
Net −8.3%
FCF −11.7%
Q3 '25
Gross 23.6%
Operating −11.4%
Net 116.5%
FCF −81.5%
Q4 '25
Gross 17.5%
Operating −9.6%
Net −13.2%
FCF −15.2%
Q1 '26
Gross 21.0%
Operating −4.4%
Net 3.2%
FCF −1.9%
Q2 '26
Gross 21.0%
Operating −7.5%
Net −14.5%
FCF 4.4%
Gross
Operating
Net
FCF
Net income and earnings per share
Loss periods are shown in red.
FY21
Net income −$40.1M
FY22
Net income —
FY23
Net income −$56.1M
FY24
Net income −$27.3M
FY25
Net income $41.3M
Q3 '23
Net income $0.3M
Q4 '23
Net income −$33.9M
Q1 '24
Net income −$4.2M
Q2 '24
Net income −$11.3M
Q3 '24
Net income −$2.0M
Q4 '24
Net income −$9.8M
Q1 '25
Net income −$3.5M
Q2 '25
Net income −$3.7M
Q3 '25
Net income $57.4M
Q4 '25
Net income −$8.8M
Q1 '26
Net income $2.2M
Q2 '26
Net income −$10.5M
FY21
Diluted EPS −$0.93
FY22
Diluted EPS —
FY23
Diluted EPS −$0.76
FY24
Diluted EPS −$0.35
FY25
Diluted EPS $0.50
Q3 '23
Diluted EPS $0.00
Q4 '23
Diluted EPS −$0.45
Q1 '24
Diluted EPS −$0.06
Q2 '24
Diluted EPS −$0.15
Q3 '24
Diluted EPS −$0.03
Q4 '24
Diluted EPS −$0.11
Q1 '25
Diluted EPS −$0.04
Q2 '25
Diluted EPS −$0.05
Q3 '25
Diluted EPS $0.70
Q4 '25
Diluted EPS −$0.11
Q1 '26
Diluted EPS $0.03
Q2 '26
Diluted EPS −$0.12
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
FY21
Return on capital —
Return on equity −13.8%
Return on assets −11.7%
FY22
Return on capital —
Return on equity —
Return on assets —
FY23
Return on capital —
Return on equity −22.0%
Return on assets −18.1%
FY24
Return on capital —
Return on equity −12.0%
Return on assets −9.9%
FY25
Return on capital —
Return on equity 16.5%
Return on assets 14.2%
Return on capital
Return on equity
Return on assets
Cash flow
Free cash flow was −$58.5M in fiscal 2025, −29.7% of revenue. Cash from operations minus capital spending.
FY21
Free cash flow −$15.9M
FY22
Free cash flow —
FY23
Free cash flow −$34.5M
FY24
Free cash flow −$33.4M
FY25
Free cash flow −$58.5M
Q3 '23
Free cash flow $1.3M
Q4 '23
Free cash flow −$9.3M
Q1 '24
Free cash flow −$16.4M
Q2 '24
Free cash flow −$7.7M
Q3 '24
Free cash flow −$3.0M
Q4 '24
Free cash flow −$6.3M
Q1 '25
Free cash flow −$2.9M
Q2 '25
Free cash flow −$5.3M
Q3 '25
Free cash flow −$40.2M
Q4 '25
Free cash flow −$10.2M
Q1 '26
Free cash flow −$1.3M
Q2 '26
Free cash flow $3.2M
FY21
Cash from operations −$15.6M
Capital spending $0.3M
FY22
Cash from operations —
Capital spending —
FY23
Cash from operations −$32.3M
Capital spending $2.1M
FY24
Cash from operations −$2.5M
Capital spending $30.9M
FY25
Cash from operations −$48.9M
Capital spending $9.6M
Cash from operations
Capital spending
Q3 '23
Cash from operations $2.0M
Capital spending $0.7M
Q4 '23
Cash from operations −$9.3M
Capital spending $0.0M
Q1 '24
Cash from operations −$15.6M
Capital spending $0.8M
Q2 '24
Cash from operations $8.4M
Capital spending $16.2M
Q3 '24
Cash from operations $6.4M
Capital spending $9.3M
Q4 '24
Cash from operations −$1.8M
Capital spending $4.6M
Q1 '25
Cash from operations −$0.2M
Capital spending $2.6M
Q2 '25
Cash from operations −$3.1M
Capital spending $2.2M
Q3 '25
Cash from operations −$37.3M
Capital spending $2.9M
Q4 '25
Cash from operations −$8.3M
Capital spending $1.8M
Q1 '26
Cash from operations $3.9M
Capital spending $5.2M
Q2 '26
Cash from operations $5.7M
Capital spending $2.5M
Cash from operations
Capital spending
Dividends, buybacks and share count
Strata Critical Medical, Inc. returned $0.0M to shareholders in fiscal 2025. The diluted share count rose 5.9%.
FY21
Dividends —
Buybacks —
FY22
Dividends —
Buybacks —
FY23
Dividends —
Buybacks $0.0M
FY24
Dividends —
Buybacks $0.2M
FY25
Dividends —
Buybacks $0.0M
Dividends
Buybacks
Q3 '23
Dividends —
Buybacks $0.0M
Q4 '23
Dividends —
Buybacks $0.0M
Q1 '24
Dividends —
Buybacks —
Q2 '24
Dividends —
Buybacks —
Q3 '24
Dividends —
Buybacks $0.0M
Q4 '24
Dividends —
Buybacks $0.0M
Q1 '25
Dividends —
Buybacks —
Q2 '25
Dividends —
Buybacks —
Q3 '25
Dividends —
Buybacks $0.0M
Q4 '25
Dividends —
Buybacks $0.0M
Q1 '26
Dividends —
Buybacks —
Q2 '26
Dividends —
Buybacks —
Dividends
Buybacks
FY21
Diluted shares 0.04B
FY22
Diluted shares —
FY23
Diluted shares 0.07B
FY24
Diluted shares 0.08B
FY25
Diluted shares 0.08B
Balance sheet
Cash, debt and the ratios that show how comfortably Strata Critical Medical, Inc. can carry it.
FY21
Cash $304M
Debt —
FY22
Cash $192M
Debt $0.0M
FY23
Cash $166M
Debt —
FY24
Cash $127M
Debt —
FY25
Cash $61.2M
Debt —
Cash
Debt
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $304M | $192M | $166M | $127M | $61.2M |
| Debt incl. finance leases | — | $0.0M | — | — | — |
| Debt / equity | — | 0.0x | — | — | — |
| Current ratio | 33.0x | 8.2x | 5.8x | 7.1x | 6.4x |
| Quick ratio | 33.0x | 8.2x | 5.8x | 7.1x | 6.4x |
| Total assets | $343M | $325M | $295M | $257M | $325M |
| Total liabilities | $52.2M | $50.5M | $60.6M | $34.7M | $46.4M |
| Shareholders' equity | $291M | $274M | $234M | $222M | $279M |
| Net debt (− = net cash) | — | −$192M | — | — | — |
Insider trades
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. 'Plan' marks trades under a pre-arranged Rule 10b5-1 plan.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
No open-market insider trades in the last 12 months.
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8–9 is strong, 0–2 weak.
| Test | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Net income is positive | ✕ | — | ✕ | ✕ | ✓ |
| Cash from operations is positive | ✕ | — | ✕ | ✕ | ✕ |
| Return on assets rose | — | — | — | ✓ | ✓ |
| Cash from operations exceeds net income | ✓ | — | ✓ | ✓ | ✕ |
| Debt fell relative to assets | — | — | — | — | — |
| Current ratio rose | — | ✕ | ✕ | ✓ | ✕ |
| Share count didn't rise | — | — | — | ✕ | ✕ |
| Gross margin rose | — | — | — | ✓ | ✓ |
| Revenue rose relative to assets | — | — | — | ✕ | ✓ |
| F-score | — / 3 | — / 1 | — / 4 | 4 / 8 | 4 / 8 |
| Accruals ratio | −7.1% | — | −7.7% | −9.0% | 31.0% |
| Altman Z'' | 10.48 | — | 4.54 | 7.27 | 6.54 |
5 years of figures
US$ millions unless stated. Hover a ratio's name for its definition.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $50.5M | — | $225M | $147M | $197M |
| Net interest income | $0.5M | — | $8.4M | $7.2M | — |
| Gross profit | $10.5M | — | $42.1M | $29.6M | $41.1M |
| Operating income | −$24.1M | — | −$68.1M | −$22.5M | −$22.4M |
| Pretax income | −$43.7M | — | −$57.5M | −$16.2M | −$20.1M |
| Income tax | −$3.6M | — | −$1.5M | $0.0M | $0.0M |
| Net income | −$40.1M | — | −$56.1M | −$27.3M | $41.3M |
| Diluted EPS | −$0.93 | — | −$0.76 | −$0.35 | $0.50 |
| Diluted shares | 0.04B | — | 0.07B | 0.08B | 0.08B |
| Cash flow | |||||
| Cash from operations | −$15.6M | — | −$32.3M | −$2.5M | −$48.9M |
| Capital expenditure | $0.3M | — | $2.1M | $30.9M | $9.6M |
| Free cash flow | −$15.9M | — | −$34.5M | −$33.4M | −$58.5M |
| Depreciation and amortization | $0.6M | — | $7.1M | $6.0M | $8.2M |
| Stock-based compensation | $9.6M | — | $12.5M | $19.9M | $17.8M |
| Acquisitions | $23.1M | — | $0.0M | $2.2M | $66.5M |
| Share buybacks | — | — | $0.0M | $0.2M | $0.0M |
| Dividends and buybacks | — | — | $0.0M | $0.2M | $0.0M |
| Balance sheet | |||||
| Cash and short-term investments | $304M | $192M | $166M | $127M | $61.2M |
| Total debt | — | $0.0M | — | — | — |
| Current assets | $314M | $218M | $206M | $161M | $126M |
| Current liabilities | $9.5M | $26.6M | $35.5M | $22.7M | $19.8M |
| Property and equipment, net | $2.0M | $2.0M | $2.9M | $28.5M | $36.4M |
| Goodwill | $13.3M | $39.4M | $13.3M | $15.5M | $88.2M |
| Intangible assets | $12.6M | $46.4M | $20.5M | $8.0M | $47.5M |
| Total assets | $343M | $325M | $295M | $257M | $325M |
| Total liabilities | $52.2M | $50.5M | $60.6M | $34.7M | $46.4M |
| Preferred stock | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Shareholders' equity | $291M | $274M | $234M | $222M | $279M |
| Margins | |||||
| Gross margin | 20.8% | — | 18.7% | 20.2% | 20.9% |
| Operating margin | −47.7% | — | −30.3% | −15.3% | −11.3% |
| EBITDA margin | −46.5% | — | −27.1% | −11.3% | −7.2% |
| Net margin | −79.3% | — | −24.9% | −18.6% | 21.0% |
| FCF margin | −31.5% | — | −15.3% | −22.7% | −29.7% |
| Net interest share of revenue | 0.9% | — | 3.7% | 4.9% | — |
| Returns | |||||
| Return on capital employed | −7.2% | — | −26.3% | −9.6% | −7.3% |
| Return on equity | −13.8% | — | −22.0% | −12.0% | 16.5% |
| Return on assets | −11.7% | — | −18.1% | −9.9% | 14.2% |
| Return on tangible equity | −15.1% | — | −28.0% | −13.8% | 28.8% |
| Growth | |||||
| Revenue growth | — | — | — | −34.8% | 34.3% |
| Share count change | — | — | — | 5.4% | 5.9% |
| Financial health | |||||
| Debt / equity | — | 0.0x | — | — | — |
| Current ratio | 33.0x | 8.2x | 5.8x | 7.1x | 6.4x |
| Quick ratio | 33.0x | 8.2x | 5.8x | 7.1x | 6.4x |
| Capital allocation | |||||
| Capex / revenue | 0.6% | — | 0.9% | 21.0% | 4.9% |
| Stock comp / revenue | 19.0% | — | 5.6% | 13.5% | 9.0% |
| Quality scores | |||||
| Piotroski F-score | — | — | — | 4.0 | 4.0 |
| Altman Z'' | 10.5 | — | 4.5 | 7.3 | 6.5 |
| Accruals ratio | −7.1% | — | −7.7% | −9.0% | 31.0% |
Source: SEC EDGAR XBRL filings (CIK 0001779128). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only — not investment advice. Check the original filings before relying on any figure.